大会发言: Abstract LBA 1006 Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER.

14:50-15:15

丰大酒店3层国际厅

乳腺癌专场2

大会发言: Abstract 1005 Everolimus (EVE) + Exemestane (EXE) vs EVE Alone or Capecitabine (CAP) for Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2-negative (HER2-) Advanced Breast Cancer (ABC): BOLERO-6, an Open-label Phase 2 Study.

14:50-15:15

丰大酒店3层国际厅

乳腺癌专场2

大会发言: Abstract 1007 AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial.

14:50-15:15

丰大酒店3层国际厅

乳腺癌专场2